pbs_code
string | drug
string | brand
string | formulation
string | indication
string | treatment_phase
string | streamlined_code
string | online_application
bool | authority_method
string | hospital_type
string | schedule_code
int64 | schedule_year
int64 | schedule_month
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
9663N | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9663N | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Public | 4,469 | 2,025 | JUNE |
9671B | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9671B | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9671B | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9671B | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9671B | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9671B | Tocilizumab | Actemra | Concentrate for injection 80 mg in 4 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9672C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9672C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9672C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9672C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9672C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9672C | Tocilizumab | Actemra | Concentrate for injection 200 mg in 10 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9673D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 1 (new patient) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9673D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9673D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9673D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9673D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | First continuing treatment | null | false | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9673D | Tocilizumab | Actemra | Concentrate for injection 400 mg in 20 mL | rheumatoid arthritis | First continuing treatment - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9679K | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled syringe | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 1 (new patient) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hyrimoz | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Hadlima | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Amgevita | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
9680L | Adalimumab | Abrilada | Injection 40 mg in 0.8 mL pre-filled pen | juvenile idiopathic arthritis | Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 12 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 12 months) - balance of supply | null | true | AUTHORITY_REQUIRED | Private | 4,469 | 2,025 | JUNE |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.